Therapeuticsmd Inc (NYSEMKT:TXMD) Institutional Investor Sentiment Is 1.47

June 16, 2018 - By Vivian Park

TherapeuticsMD, Inc. (NASDAQ:TXMD) Logo

Sentiment for Therapeuticsmd Inc (NYSEMKT:TXMD)

Therapeuticsmd Inc (NYSEMKT:TXMD) institutional sentiment decreased to 1.47 in 2018 Q1. Its down -0.15, from 1.62 in 2017Q4. The ratio dropped, as 66 funds increased or opened new holdings, while 45 reduced and sold holdings in Therapeuticsmd Inc. The funds in our partner’s database reported: 160.49 million shares, up from 159.91 million shares in 2017Q4. Also, the number of funds holding Therapeuticsmd Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 28 Increased: 45 New Position: 21.

TherapeuticsMD, Inc. operates as a womenÂ’s health care product company. The company has market cap of $1.54 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

The stock increased 3.63% or $0.25 during the last trading session, reaching $7.13. About 6.64 million shares traded or 107.75% up from the average. TherapeuticsMD, Inc. (NYSEMKT:TXMD) has risen 49.88% since June 16, 2017 and is uptrending. It has outperformed by 37.31% the S&P500.

Analysts await TherapeuticsMD, Inc. (NASDAQ:TXMD) to report earnings on August, 2. They expect $-0.12 earnings per share, down 20.00 % or $0.02 from last year’s $-0.1 per share. After $-0.11 actual earnings per share reported by TherapeuticsMD, Inc. for the previous quarter, Wall Street now forecasts 9.09 % negative EPS growth.

1492 Capital Management Llc holds 1.39% of its portfolio in TherapeuticsMD, Inc. for 372,242 shares. Ardsley Advisory Partners owns 1.18 million shares or 0.86% of their US portfolio. Moreover, Trellus Management Company Llc has 0.58% invested in the company for 65,000 shares. The Massachusetts-based Capital Impact Advisors Llc has invested 0.53% in the stock. Morgens Waterfall Vintiadis & Co Inc, a New York-based fund reported 112,000 shares.

More important recent TherapeuticsMD, Inc. (NASDAQ:TXMD) news were published by: Streetinsider.com which released: “Pre-Open Stock Movers 06/15: (VSTM) (TXMD) (GLUU) Higher; (AFMD) (GBT) (GNK) Lower (more…)” on June 15, 2018, also Fool.com published article titled: “Here’s Why TherapeuticsMD Inc Jumped Today”, Benzinga.com published: “TherapeuticsMD Announces FDA Approval Of IMVEXXY — For Real This Time” on May 30, 2018. More interesting news about TherapeuticsMD, Inc. (NASDAQ:TXMD) was released by: Schaeffersresearch.com and their article: “2 Drug Stocks Squeezing Shorts” with publication date: June 15, 2018.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.